HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Clinical trials for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST explained in plain language.
Never miss a new study
Get alerted when new HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST trials appear
Sign up with your email to follow new studies for HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill aims to shrink tumors in advanced breast and ovarian cancers
Disease control Recruiting nowThis study tests an experimental pill called INX-315 in 150 people with advanced cancers, including certain breast and ovarian cancers that have stopped responding to standard treatments. The goal is to see if the drug is safe and can shrink or control tumors. The study has three…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1, PHASE2 • Sponsor: Incyclix Bio • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis early-phase study tests an experimental pill, NKT3964, designed to break down a protein (CDK2) that helps cancer cells grow. About 150 adults with advanced or metastatic solid tumors (including ovarian, endometrial, breast, gastric, and lung cancers) that have stopped respon…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE1 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New hope for nigerian women: targeted breast cancer therapy before and after surgery
Disease control Recruiting nowThis study is for Nigerian women with a specific type of breast cancer called HER2-positive. Doctors want to see if giving a combination of targeted drugs before and after surgery can destroy the cancer completely. About 74 women will receive the treatment, and researchers will c…
Matched conditions: HUMAN EPIDERMAL GROWTH FACTOR 2 NEGATIVE CARCINOMA OF BREAST
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated May 11, 2026 20:48 UTC